# Remdesivir in COVID-19 Lahore General Hospital

> **NCT04560231** · EARLY_PHASE1 · UNKNOWN · sponsor: **Lahore General Hospital** · enrollment: 30 (estimated)

## Conditions studied

- SARS-CoV Infection

## Interventions

- **DRUG:** Remdesivir

## Key facts

- **NCT ID:** NCT04560231
- **Lead sponsor:** Lahore General Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-01
- **Primary completion:** 2020-11-30
- **Final completion:** 2020-11-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04560231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04560231, "Remdesivir in COVID-19 Lahore General Hospital". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04560231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*